Medicare to Cover Weight-Loss Drugs for At-Risk Patients

Medicare will now cover weight-loss drugs like Wegovy and Zepbound for some patients at high risk of heart disease or stroke
Reverses long-standing rule excluding weight-loss drug coverage under Medicare Part D plans
Patients will still need to meet criteria to get coverage, like having history of cardiovascular disease
Big potential boost for Novo Nordisk's Wegovy and Lilly's Zepbound weight-loss drugs
Doesn't impact coverage of Ozempic, Mounjaro and other diabetes drugs already covered for many under Part D